News and Announcements
Prescient Therapeutics Appoints Steven Yatomi-Clarke as CEO
- Published February 15, 2016 12:37PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th February 2016, ASX Announcement
Clinical stage oncology company, Prescient Therapeutics Ltd (PTX) is pleased to advise that it has appointed Steven Yatomi-Clarke as Chief Executive Officer and Managing Director of the Company.
Steven has a distinguished career in the Australian capital markets with a particular focus on the life sciences sector, where he has played a leading role as both a corporate advisor and fund raiser to many biotechnology companies. Educated at the University of Melbourne, where he earned a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, he has the rare distinction of readily bridging the divide between science and commerce.
Steven leaves behind a very successful career as Director in Corporate Finance of leading Australian broker, Patersons Securities. Steven said, “I’m honoured to accept the invitation to lead PTX. The impeccable science behind our programs;the world class scientific and clinical personnel involved and the fact that our programs are already in several clinical trials with imminent catalysts made it an opportunity that was impossible to resist.”
To read the full announcement, please click here.